Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
ADP-Ribosylation Factor 1 | 1 | 2016 | 43 | 0.540 |
Why?
|
Receptor, trkB | 1 | 2016 | 124 | 0.500 |
Why?
|
Killer Cells, Natural | 2 | 2016 | 2211 | 0.490 |
Why?
|
Morpholines | 3 | 2018 | 584 | 0.460 |
Why?
|
Brain Neoplasms | 6 | 2023 | 9118 | 0.420 |
Why?
|
Neoplasms, Experimental | 2 | 2020 | 1230 | 0.410 |
Why?
|
Aminopyridines | 1 | 2016 | 580 | 0.400 |
Why?
|
Astrocytoma | 1 | 2016 | 774 | 0.380 |
Why?
|
PTEN Phosphohydrolase | 4 | 2020 | 1120 | 0.360 |
Why?
|
Multiprotein Complexes | 2 | 2016 | 1110 | 0.350 |
Why?
|
Antineoplastic Agents | 3 | 2022 | 13677 | 0.350 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2016 | 2062 | 0.330 |
Why?
|
Astrocytes | 1 | 2016 | 1350 | 0.300 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2016 | 1613 | 0.300 |
Why?
|
RNA-Binding Proteins | 1 | 2016 | 1891 | 0.280 |
Why?
|
Vitamin E | 2 | 2009 | 874 | 0.280 |
Why?
|
Apoptosis | 4 | 2020 | 9527 | 0.270 |
Why?
|
Breast Neoplasms | 6 | 2023 | 21207 | 0.270 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2021 | 905 | 0.270 |
Why?
|
Phosphatidylinositol 3-Kinases | 6 | 2020 | 2885 | 0.260 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 710 | 0.260 |
Why?
|
Receptor, erbB-2 | 4 | 2023 | 2603 | 0.250 |
Why?
|
Membrane Glycoproteins | 1 | 2016 | 3713 | 0.250 |
Why?
|
Enzyme Inhibitors | 3 | 2012 | 3728 | 0.240 |
Why?
|
Neoplasm Transplantation | 4 | 2016 | 2014 | 0.230 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 2 | 2016 | 77 | 0.230 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2024 | 42 | 0.230 |
Why?
|
Pentose Phosphate Pathway | 1 | 2024 | 126 | 0.220 |
Why?
|
Protein Isoforms | 3 | 2020 | 1715 | 0.220 |
Why?
|
Nicotinamide N-Methyltransferase | 1 | 2022 | 10 | 0.210 |
Why?
|
Immunotherapy, Adoptive | 1 | 2012 | 1512 | 0.200 |
Why?
|
Mice, Nude | 5 | 2018 | 3623 | 0.190 |
Why?
|
Lipoproteins | 1 | 2005 | 880 | 0.180 |
Why?
|
Niacinamide | 1 | 2022 | 418 | 0.170 |
Why?
|
Mice | 20 | 2024 | 82049 | 0.170 |
Why?
|
Cell Line, Tumor | 11 | 2020 | 17142 | 0.170 |
Why?
|
Receptors, Androgen | 4 | 2009 | 1089 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2020 | 3612 | 0.160 |
Why?
|
Prostatic Neoplasms | 6 | 2009 | 11101 | 0.160 |
Why?
|
Carrier Proteins | 2 | 2016 | 4939 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 565 | 0.150 |
Why?
|
Eukaryotic Initiation Factors | 1 | 2016 | 83 | 0.130 |
Why?
|
Neoplastic Stem Cells | 1 | 2024 | 1351 | 0.130 |
Why?
|
Trans-Activators | 1 | 2005 | 2857 | 0.130 |
Why?
|
Receptors, Glutamate | 1 | 2016 | 229 | 0.130 |
Why?
|
Membrane Microdomains | 1 | 2016 | 205 | 0.120 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2016 | 246 | 0.120 |
Why?
|
Immunoconjugates | 1 | 2023 | 975 | 0.120 |
Why?
|
Animals | 20 | 2024 | 169285 | 0.120 |
Why?
|
CCAAT-Enhancer-Binding Protein-beta | 1 | 2014 | 102 | 0.110 |
Why?
|
Ki-67 Antigen | 1 | 2016 | 630 | 0.110 |
Why?
|
Caspase 3 | 1 | 2016 | 730 | 0.110 |
Why?
|
Histone Deacetylases | 1 | 2018 | 717 | 0.110 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 778 | 0.110 |
Why?
|
Mammary Glands, Human | 1 | 2014 | 202 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2018 | 5341 | 0.100 |
Why?
|
Cyclin D1 | 1 | 2014 | 453 | 0.100 |
Why?
|
Oncogene Protein v-akt | 1 | 2012 | 130 | 0.100 |
Why?
|
Keratinocytes | 1 | 2016 | 876 | 0.100 |
Why?
|
Interleukin-15 | 1 | 2012 | 186 | 0.100 |
Why?
|
Genomic Instability | 1 | 2016 | 716 | 0.100 |
Why?
|
Nuclear Receptor Subfamily 2, Group C, Member 2 | 1 | 2011 | 2 | 0.100 |
Why?
|
Interleukin-18 | 1 | 2012 | 251 | 0.090 |
Why?
|
Mice, SCID | 1 | 2016 | 2627 | 0.090 |
Why?
|
Neuropeptides | 1 | 2016 | 951 | 0.090 |
Why?
|
Phagocytosis | 1 | 2016 | 1530 | 0.090 |
Why?
|
Mice, Knockout | 3 | 2016 | 14488 | 0.090 |
Why?
|
High-Throughput Screening Assays | 1 | 2016 | 942 | 0.090 |
Why?
|
DNA Repair | 2 | 2018 | 2050 | 0.090 |
Why?
|
Remission Induction | 1 | 2016 | 2410 | 0.090 |
Why?
|
Indazoles | 1 | 2012 | 306 | 0.090 |
Why?
|
Interleukin-12 | 1 | 2012 | 577 | 0.090 |
Why?
|
Immunohistochemistry | 4 | 2019 | 11095 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2024 | 2459 | 0.080 |
Why?
|
NF-kappa B | 1 | 2018 | 2494 | 0.080 |
Why?
|
Melanoma, Experimental | 1 | 2012 | 559 | 0.080 |
Why?
|
Foam Cells | 1 | 2009 | 68 | 0.080 |
Why?
|
Myeloproliferative Disorders | 1 | 2015 | 616 | 0.080 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2018 | 1339 | 0.080 |
Why?
|
Receptors, Steroid | 1 | 2009 | 156 | 0.080 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2009 | 202 | 0.080 |
Why?
|
Sulfonic Acids | 1 | 2009 | 103 | 0.080 |
Why?
|
alpha-Tocopherol | 1 | 2009 | 127 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2024 | 3626 | 0.080 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2541 | 0.080 |
Why?
|
DNA Damage | 1 | 2018 | 2469 | 0.070 |
Why?
|
Adaptive Immunity | 1 | 2012 | 733 | 0.070 |
Why?
|
Phosphorylation | 2 | 2016 | 8316 | 0.070 |
Why?
|
Leukemia | 1 | 2015 | 1519 | 0.070 |
Why?
|
Phosphoproteins | 1 | 2016 | 2451 | 0.070 |
Why?
|
Cell Cycle Proteins | 2 | 2016 | 3445 | 0.070 |
Why?
|
Cell Membrane | 1 | 2016 | 3655 | 0.070 |
Why?
|
Spleen | 1 | 2012 | 2296 | 0.070 |
Why?
|
Receptors, Calcitriol | 1 | 2009 | 361 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2015 | 2592 | 0.070 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2009 | 542 | 0.070 |
Why?
|
Humans | 24 | 2024 | 768171 | 0.070 |
Why?
|
Hematopoiesis | 1 | 2015 | 2059 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 6316 | 0.060 |
Why?
|
Tumor Burden | 1 | 2012 | 1906 | 0.060 |
Why?
|
Interleukin-2 | 1 | 2012 | 1895 | 0.060 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2909 | 0.060 |
Why?
|
Glioblastoma | 1 | 2020 | 3464 | 0.060 |
Why?
|
Cell Proliferation | 2 | 2012 | 10478 | 0.060 |
Why?
|
Cell Growth Processes | 1 | 2005 | 381 | 0.060 |
Why?
|
MAP Kinase Signaling System | 2 | 2016 | 1495 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2830 | 0.060 |
Why?
|
Interferon-gamma | 1 | 2012 | 3161 | 0.060 |
Why?
|
Flutamide | 1 | 2004 | 95 | 0.060 |
Why?
|
Cells, Cultured | 2 | 2016 | 19025 | 0.060 |
Why?
|
Lymphoma | 1 | 2012 | 1898 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 1 | 2015 | 3409 | 0.050 |
Why?
|
Glioma | 1 | 2018 | 3503 | 0.050 |
Why?
|
Neoplasms | 1 | 2012 | 22371 | 0.050 |
Why?
|
Cell Nucleus | 2 | 2009 | 2885 | 0.050 |
Why?
|
Cell Differentiation | 2 | 2014 | 11677 | 0.050 |
Why?
|
Cell Line | 2 | 2016 | 15602 | 0.050 |
Why?
|
Sulfonamides | 1 | 2012 | 1982 | 0.050 |
Why?
|
Gene Expression | 2 | 2005 | 7601 | 0.050 |
Why?
|
Blood-Brain Barrier | 2 | 2019 | 1035 | 0.050 |
Why?
|
Aging | 1 | 2021 | 8743 | 0.050 |
Why?
|
Cyclins | 1 | 2004 | 606 | 0.050 |
Why?
|
Signal Transduction | 4 | 2024 | 23648 | 0.050 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2024 | 381 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2892 | 0.050 |
Why?
|
Administration, Oral | 1 | 2009 | 4034 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2012 | 8542 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2012 | 3080 | 0.040 |
Why?
|
Epilepsy | 1 | 2015 | 3326 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9540 | 0.040 |
Why?
|
Oncogene Proteins | 1 | 2004 | 717 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2012 | 4415 | 0.040 |
Why?
|
Methylation | 1 | 2022 | 1078 | 0.040 |
Why?
|
Female | 8 | 2023 | 397187 | 0.040 |
Why?
|
Camptothecin | 1 | 2023 | 600 | 0.040 |
Why?
|
Cell Survival | 1 | 2009 | 5789 | 0.040 |
Why?
|
Transcriptional Activation | 3 | 2011 | 1750 | 0.040 |
Why?
|
Forkhead Transcription Factors | 1 | 2005 | 1625 | 0.040 |
Why?
|
Mice, Inbred C57BL | 2 | 2014 | 22380 | 0.040 |
Why?
|
Blotting, Western | 3 | 2015 | 5028 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2005 | 2393 | 0.040 |
Why?
|
Transcription Factors | 3 | 2012 | 12171 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11878 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2018 | 348 | 0.030 |
Why?
|
Brain | 2 | 2021 | 27362 | 0.030 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2016 | 179 | 0.030 |
Why?
|
Protein Binding | 3 | 2014 | 9343 | 0.030 |
Why?
|
rac GTP-Binding Proteins | 1 | 2015 | 163 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2004 | 3229 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18349 | 0.030 |
Why?
|
Binding Sites | 1 | 2022 | 6019 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2015 | 488 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2004 | 2956 | 0.030 |
Why?
|
Ligands | 2 | 2011 | 3284 | 0.030 |
Why?
|
Chemotaxis | 1 | 2015 | 600 | 0.030 |
Why?
|
Male | 8 | 2020 | 364731 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2004 | 3604 | 0.020 |
Why?
|
Cytoskeleton | 1 | 2016 | 1179 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2018 | 1312 | 0.020 |
Why?
|
Time Factors | 1 | 2012 | 40220 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2004 | 5804 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 36741 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 693 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6525 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 2 | 2012 | 2810 | 0.020 |
Why?
|
Response Elements | 1 | 2009 | 308 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2011 | 1683 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2009 | 12801 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2023 | 65379 | 0.020 |
Why?
|
Models, Biological | 2 | 2018 | 9497 | 0.020 |
Why?
|
Tumor Cells, Cultured | 2 | 2004 | 6124 | 0.020 |
Why?
|
Lysine | 1 | 2011 | 1000 | 0.020 |
Why?
|
Thiazolidinediones | 1 | 2009 | 461 | 0.020 |
Why?
|
Fibroblasts | 1 | 2016 | 4178 | 0.020 |
Why?
|
Pyrimidines | 1 | 2018 | 3048 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3948 | 0.020 |
Why?
|
Chromones | 1 | 2005 | 148 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2012 | 2004 | 0.020 |
Why?
|
Bone Marrow | 1 | 2015 | 2935 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2015 | 5902 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2014 | 4280 | 0.010 |
Why?
|
Contactins | 1 | 2004 | 21 | 0.010 |
Why?
|
Androgen Receptor Antagonists | 1 | 2005 | 123 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2011 | 3772 | 0.010 |
Why?
|
Kinetics | 1 | 2012 | 6330 | 0.010 |
Why?
|
Neural Cell Adhesion Molecules | 1 | 2004 | 122 | 0.010 |
Why?
|
Nuclear Receptor Coactivators | 1 | 2004 | 62 | 0.010 |
Why?
|
Drug Stability | 1 | 2004 | 292 | 0.010 |
Why?
|
Consensus Sequence | 1 | 2004 | 363 | 0.010 |
Why?
|
Two-Hybrid System Techniques | 1 | 2004 | 463 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2011 | 1966 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 379 | 0.010 |
Why?
|
Phenotype | 1 | 2021 | 16726 | 0.010 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2005 | 858 | 0.010 |
Why?
|
COS Cells | 1 | 2004 | 1135 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 41753 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2004 | 2474 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10763 | 0.010 |
Why?
|
Plasmids | 1 | 2004 | 2269 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2004 | 3056 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2005 | 8648 | 0.010 |
Why?
|
Base Sequence | 1 | 2009 | 12422 | 0.010 |
Why?
|
Prospective Studies | 1 | 2023 | 54924 | 0.010 |
Why?
|
Proteomics | 1 | 2012 | 3912 | 0.010 |
Why?
|
DNA | 1 | 2011 | 7213 | 0.010 |
Why?
|
Proteins | 1 | 2012 | 6009 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 17623 | 0.010 |
Why?
|
Down-Regulation | 1 | 2004 | 2939 | 0.010 |
Why?
|
Androgens | 1 | 2004 | 1281 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 4477 | 0.010 |
Why?
|
Transfection | 1 | 2004 | 5756 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2005 | 3428 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 30237 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 2005 | 2463 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2009 | 7609 | 0.010 |
Why?
|
Androgen Antagonists | 1 | 2004 | 1412 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2012 | 9617 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2005 | 5797 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2023 | 81760 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2004 | 13422 | 0.010 |
Why?
|
Child | 1 | 2018 | 80917 | 0.010 |
Why?
|
Disease Progression | 1 | 2004 | 13668 | 0.000 |
Why?
|